Clinical Trial Update: Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 1/2 safety study evaluating inhaled 552-02 in patients with cystic fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• 552-02

Snippet

Sponsor: Parion Sciences | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: COMPLETED